ACOTEC-B (Acotec Scientific Holdings) reported a net loss of RMB 80.83 million for the six months ended 30 June 2026, reversing a RMB 88.58 million profit a year earlier. The downturn was driven primarily by a one-off RMB 150.80 million impairment and related provisions following the discontinuation of the company’s U.S. clinical trial for the AcoArt Litos® paclitaxel-coated balloon.

Revenue fell 5.6 % year-on-year to RMB 331.58 million. Arterial intervention sales—dominated by drug-coated balloons—dropped 32.4 % to RMB 140.78 million after price cuts under China’s Sixth National Volume-Based Procurement (VBP). In contrast, venous intervention, vascular access and other product lines rose 36.0 % to RMB 190.80 million, supported by wider domestic hospital penetration and initial U.S. contributions from the radiofrequency ablation system launched in late 2025.

Gross profit declined 10.5 % to RMB 233.18 million, and gross margin narrowed 3.9 percentage points to 70.3 % on VBP pricing and product mix shifts. Research and development expenses more than doubled to RMB 239.39 million, reflecting the Litos® write-off and higher project spending. Selling and distribution costs fell 26.8 % to RMB 40.82 million, while administrative expenses dropped 14.0 % to RMB 32.49 million.

Excluding share-based payments, foreign-exchange losses and the Litos® charge, non-IFRS adjusted net profit slipped 9.0 % to RMB 90.60 million.

Financially, ACOTEC-B held RMB 854.80 million in cash, time deposits and short-term investments at 30 June 2026, down 9.8 % from end-2025, and reported net current assets of RMB 1.07 billion. Interest-bearing bank borrowings stood at RMB 30.00 million. The gearing ratio edged up to 27.8 % on higher trade payables. No interim dividend was declared.

Operationally, the company’s portfolio totals 32 commercialised products across vascular surgery, cardiology, nephrology, neurology and oncology, with coverage in more than 3,000 hospitals in mainland China and registrations in over 30 overseas markets. Management highlighted ongoing collaboration with Boston Scientific Group and reiterated plans to expand global registrations and advance late-stage pipeline assets, including a coronary intravascular lithotripsy system and sirolimus-coated balloons.